Medigene AG

MDG1

DE000A1X3W00

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 09:30:00 2024-07-02 EDT			5-day change	1st Jan Change
1.128 ^EUR	+1.17%		-1.74%	-25.90%

06-27	Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	CI
05-21	Medigene, BioNTech Extend Cancer Immunotherapy Partnership	MT

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

May 12, 2022 at 12:40 pm

Medigene AG appointed Dr. Selwyn Ho as a member of the Executive Management Board with effect of 25 July 2022. He accepted the appointments.

Latest news about Medigene AG

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	06-27	CI
Medigene, BioNTech Extend Cancer Immunotherapy Partnership	05-21	MT
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	05-21	CI
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	05-15	CI
Medigene Ag Maintains Earnings Guidance for 2024	05-14	CI
Medigene Boosts Share Capital Via Rights Offering, Private Placement	05-08	MT
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	05-02	CI
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	05-02	CI
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	04-25	CI
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	04-08	CI
Medigene Gets European Patent for T-Cell Receptor Technology	04-04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	04-04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024	03-28
Medigene Ag Provides Earnings Guidance for 2024	03-28	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	03-04	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	02-12	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	11-21	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	11-04	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23-10-23	CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023	23-10-16	CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types	23-08-23	CI
Medigene AG Provides Revenue Guidance for 2023	23-08-17	CI
Transcript : Medigene AG, H1 2023 Earnings Call, Aug 17, 2023	23-08-17
Medigene AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Medigene AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.115 EUR

Average target price

2.675 EUR

Spread / Average Target

+139.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDIGENE AG	-25.90%	35.25M
VERTEX PHARMACEUTICALS INCORPORATED	+15.82%	122B
REGENERON PHARMACEUTICALS, INC.	+20.35%	114B
ARGENX SE	+18.54%	25.71B
BIONTECH SE	-25.31%	19.02B
GENMAB A/S	-20.72%	15.83B
BEIGENE, LTD.	-19.67%	15.32B
WUXI APPTEC CO., LTD.	-46.87%	14.88B
SAREPTA THERAPEUTICS, INC.	+62.55%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+6.34%	14.1B

Bio Therapeutic Drugs

Medigene AG

Equities

MDG1

DE000A1X3W00

Biotechnology & Medical Research

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Latest news about Medigene AG

Chart Medigene AG

Company Profile

Income Statement Evolution

Ratings for Medigene AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs